DaVita Inc. stock extends recent gains as investors weigh ransomware settlement and 2026 guidance | #hacking | #cybersecurity | #infosec | #comptia | #pentest | #ransomware

DaVita Inc. stock (ISIN US23918K1088) ended trading on the New York Stock Exchange at USD 189.32 on September 15, 2026, roughly 4.4 percent above the previous close and reinforcing a strong year-to-date performance profile for the dialysis provider.

Stock reacts to ransomware settlement news

As MarketBeat highlights via recent news aggregation dated September 4, 2026, DaVita reached a preliminary settlement agreement in a class action related to a prior ransomware attack, a development that helps investors quantify legal risk around the incident.

The settlement headlines have coincided with a recovery in DaVita Inc. stock from a 52-week low of USD 101.00 toward the mid-USD 180 range, leaving the shares still materially below the cited 52-week high of USD 247.49 as of September 15, 2026, based on a NYSE price snapshot reported in ad-hoc market coverage.

Latest earnings and guidance frame valuation

According to MarketBeat, DaVita most recently reported quarterly results for the period ending June 30, 2026, in its second-quarter 2026 update published on August 4, 2026, which investors now use as the primary fundamental reference.

In that second quarter of 2026, the company generated revenue that was higher than the comparable quarter in 2025 and reported earnings per share consistent with its full-year trajectory, placing its business within the current freshness window for fundamental figures.

Per the same institutional overview from MarketBeat, DaVita communicated full-year 2026 earnings guidance with a range of USD 14.10 to USD 15.20 in earnings per share, which investors compare with the prior year’s performance to assess growth and valuation.

The midpoint of that guidance range implies an EPS level around USD 14.65 for 2026, and investors benchmark that against historical earnings to gauge how far the business has progressed since earlier years.

Analyst price target adjustments and risk perception

As aggregated by MarketBeat, one of the latest notable analyst actions came from Bank of America, which adjusted its price target on DaVita from USD 170 to USD 180 on September 15, 2026, reflecting a higher valuation view while still placing the target below the current share price.

This move by Bank of America signals that at least one major analyst house now sees more upside in DaVita’s fundamentals than previously, even though the new USD 180 target remains slightly under the September 15, 2026 closing level of USD 189.32.

Against that backdrop, DaVita Inc. stock trades at a modest premium to the freshly raised USD 180 price target, suggesting that the market currently prices in either stronger medium-term earnings delivery or reduced risk relative to earlier expectations.

At the same time, the mention of a ransomware-related class settlement in recent headlines, as captured in the aggregated news feed on MarketBeat, keeps cyber security and litigation exposure on investors’ radar as a tangible risk factor alongside reimbursement trends and regulatory oversight in the US healthcare system.

Trading metrics, 52-week range and market capitalization

DaVita Inc. stock most recently traded between an intraday low of USD 184.00 and an intraday high of USD 189.95 on September 15, 2026, with volume around 684,000 shares on the NYSE, according to ad-hoc market coverage citing NYSE data for that session.

That session’s close at USD 189.32 left the stock well above its 52-week low of USD 101.00 and still meaningfully below the referenced 52-week high of USD 247.49 as of September 15, 2026, illustrating a recovery phase that has not yet brought the shares back to their previous peak.

The same price snapshot cited a market capitalization near USD 12.1 billion for DaVita Inc. as of September 15, 2026, based on the prevailing share price and shares outstanding, reinforcing its status as a mid-cap healthcare services provider with meaningful scale in the US dialysis market.

Macro backdrop and sector positioning

Per broader market commentary referenced in recent coverage, US equity indexes closed lower on September 15, 2026 as investors monitored interest rates and energy prices, an environment that can influence valuations for defensive sectors such as healthcare.

DaVita Inc. stock’s ability to advance roughly 4.4 percent on that same day, despite pressure on the broader market, suggests that company-specific factors such as clarified legal risk and visible 2026 guidance currently outweigh macro headwinds in investors’ assessment.

For many portfolio managers, the combination of a clearly communicated EPS range for full-year 2026 and the updated analyst price target provides concrete checkpoints to reassess DaVita’s risk-reward profile within the healthcare space.

DaVita Inc. stock price snapshot

As of the most recent completed trading day on September 15, 2026, DaVita Inc. stock closed at USD 189.32 on the NYSE, up about 4.4 percent from the prior session’s close, with intraday trading between USD 184.00 and USD 189.95 and a cited market capitalization near USD 12.1 billion in that price overview.

More news and analyses on DaVita Inc. stock